According to the business intelligence report titled ‘Global Influenza Vaccines Market 2019-2028’, available with Market Study Report, global influenza vaccines market is estimated to grow at a yearly rate of 6.20% CAGR between 2019-2028.
 

Technological developments and increasing number of immunization programs by governments to raise awareness regarding importance of vaccination are the key factors driving global influenza vaccines market outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3552768/
 

While increasing cases of influenza across the world will facilitate revenue inflow, high cost of development of vaccines, complex nature of the manufacturing process, and stringent government regulations will act as challenges for this business sphere.
 

The research report provides an exhaustive analysis of the market by diving it into segments. Detailed information regarding market share held, estimated growth rate, and revenue garnered by each segment is incorporated as well.
 

Based on type, worldwide influenza vaccine marketplace is split into trivalent vaccine, and quadrivalent vaccine. Speaking of technology, the industry is divided into cell-based technology, and egg-based technology.
 

As per age group, the business sphere is bifurcated into adult, and pediatric. Moving on to delivery mode, the market sphere is fragmented into nasal spray, and injection.  
 

From the regional frame of reference, Asia Pacific market is anticipated to witness significant expansion between 2019-2028, primarily due to increasing incidence of influenza and growing healthcare expenditure in China, India, and Japan. Surging investments in research & development by leading players along with favorable government initiatives to boost vaccine development will aid industry growth as well.
 

Key players formulating the competitive landscape of global influenza vaccines marketplace are CSL Limited, Novartis International AG, Merck Sharp & Dohme Corporation, Sanofi S.A., Pfizer Inc., Abbott Laboratories, BioDiem Limited, GlaxoSmithKline plc, F. Hoffmann La-Roche AG, and Emergent BioSolutions Inc.